title: [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].
abstract: Pancreatic ductal carcinoma is a highly aggressive cancer, with one of the highest mortality rates among gastrointestinal cancers. Nab-paclitaxel plus gemcitabine (GEM) significantly improved overall survival, progression-free survival, and response rate in a phase Ⅲ trial in 151 community and academic centers in 11 countries. As a result, nab-paclitaxel plus GEM was approved for use in December 2014 in Japan. We report a case of a patient with pancreatic cancer who underwent this chemotherapy. A 47-year-old man was admitted to our hospital for evaluation of pancreatic lesions. Computed tomography revealed a hypoattenuating tumor in the body of the pancreas. After the patient underwent preoperative chemoradiotherapy under the diagnosis of cStage Ⅳa cancer, we planned to perform distal pancreatectomy. However, this case was inoperable because we found 3 liver metastases during surgery. On postoperative day 14, we treated the patient with nab-paclitaxel plus GEM. Grade 2 toxicities included neutropenia, diarrhea, and peripheral neuropathy, but serious adverse events did not occur. The progression-free survival was 5 months. He remained alive for 7 months after the chemotherapy. In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus GEM can be considered as the standard treatment.
authors.affiliation: Dept. of Surgery, Kansai Rosai Hospital.
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Katsura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ohmura
authors.forename: Yurina
authors.initials: Y
authors.lastname: Motoyama
authors.forename: Tomo
authors.initials: T
authors.lastname: Ishida
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Morimoto
authors.forename: Katsunori
authors.initials: K
authors.lastname: Matsushita
authors.forename: Atsushi
authors.initials: A
authors.lastname: Naito
authors.forename: Kohei
authors.initials: K
authors.lastname: Murakami
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kagawa
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Okishiro
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeno
authors.forename: Chiyomi
authors.initials: C
authors.lastname: Egawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Tamura
mesh_terms: D000418:Albumins / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine